<li>acebutolol<p>acebutolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of acebutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>aceclofenac<p>aceclofenac and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aceclofenac and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>acemetacin<p>acemetacin and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>acemetacin and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>agrimony<p>naproxen and agrimony both increase  anticoagulation. Use Caution/Monitor.</p></li><li>albuterol<p>naproxen increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>alfalfa<p>naproxen and alfalfa both increase  anticoagulation. Use Caution/Monitor.</p></li><li>alfuzosin<p>naproxen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>alteplase<p>naproxen and alteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.</p></li><li>american ginseng<p>naproxen and american ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>amiloride<p>amiloride and naproxen both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>antithrombin alfa<p>antithrombin alfa and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>antithrombin iii<p>antithrombin iii and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>arformoterol<p>naproxen increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>argatroban<p>argatroban and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>asenapine<p>naproxen decreases effects of asenapine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>aspirin<p>aspirin and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>aspirin rectal<p>aspirin rectal and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin rectal and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin/citric acid/sodium bicarbonate and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>atenolol<p>atenolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of atenolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>azilsartan<p>naproxen, azilsartan.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.<span><br><br></span>naproxen decreases effects of azilsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.</p></li><li>bambuterol<p>naproxen increases and bambuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bemiparin<p>bemiparin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>benazepril<p>benazepril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>bendroflumethiazide<p>naproxen increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>betaxolol<p>betaxolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of betaxolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>bisoprolol<p>bisoprolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of bisoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>bivalirudin<p>bivalirudin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>budesonide<p>naproxen, budesonide.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>bumetanide<p>naproxen increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of bumetanide by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>candesartan<p>candesartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of candesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>candesartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>captopril<p>captopril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>carbenoxolone<p>naproxen increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>carvedilol<p>carvedilol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>celecoxib<p>celecoxib and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>celiprolol<p>celiprolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of celiprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>chlorothiazide<p>naproxen increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>chlorpropamide<p>naproxen increases effects of chlorpropamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>chlorthalidone<p>naproxen increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>naproxen and choline magnesium trisalicylate both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and choline magnesium trisalicylate both increase  serum potassium. Use Caution/Monitor.</p></li><li>cinnamon<p>naproxen and cinnamon both increase  anticoagulation. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>naproxen, ciprofloxacin. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Mechanism: unknown. Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.</p></li><li>citalopram<p>citalopram, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>clobetasone<p>naproxen, clobetasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>clomipramine<p>clomipramine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.</p></li><li>clopidogrel<p>clopidogrel, naproxen.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Clopidogrel and NSAIDs both inhibit platelet aggregation.</p></li><li>cordyceps<p>naproxen and cordyceps both increase  anticoagulation. Use Caution/Monitor.</p></li><li>cortisone<p>naproxen, cortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>cyclopenthiazide<p>naproxen increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>cyclosporine<p>naproxen, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>dabigatran<p>dabigatran and naproxen both increase  anticoagulation. Use Caution/Monitor. Caution is advised, both drugs have the potential to cause bleeding. Concomitant use may increase risk of bleeding.</p></li><li>dalteparin<p>dalteparin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>deferasirox<p>deferasirox, naproxen. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase GI bleeding, ulceration and irritation. Use with caution.</p></li><li>defibrotide<p>defibrotide increases effects of naproxen by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Defibrotide may enhance effects of platelet inhibitors.</p></li><li>deflazacort<p>naproxen, deflazacort.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>dexamethasone<p>naproxen, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>dichlorphenamide<p>dichlorphenamide and naproxen both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>diclofenac and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>diclofenac and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>diflunisal<p>diflunisal and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>diflunisal and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>digoxin<p>naproxen and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>dobutamine<p>naproxen increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dong quai<p>naproxen and dong quai both increase  anticoagulation. Use Caution/Monitor.</p></li><li>dopexamine<p>naproxen increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>doxazosin<p>naproxen decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>drospirenone<p>drospirenone and naproxen both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>duloxetine<p>duloxetine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>edoxaban<p>edoxaban, naproxen.
Either increases toxicity of the other by anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding, monitor closely. Promptly evaluate any signs or symptoms of blood loss.</p></li><li>eltrombopag<p>eltrombopag increases levels of naproxen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df, naproxen.
Either increases toxicity of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine and tenofovir with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.</p></li><li>emtricitabine<p>emtricitabine, naproxen.
Either increases levels of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.</p></li><li>enalapril<p>enalapril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>enoxaparin<p>enoxaparin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ephedrine<p>naproxen increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ephedrine (pulmonary)<p>naproxen increases and ephedrine (pulmonary) decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>epinephrine<p>naproxen increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>epinephrine racemic<p>naproxen increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>epoprostenol<p>naproxen and epoprostenol both increase  anticoagulation. Use Caution/Monitor.</p></li><li>eprosartan<p>eprosartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of eprosartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>eprosartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>escitalopram<p>escitalopram, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>esmolol<p>esmolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of esmolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>ethacrynic acid<p>naproxen increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>etodolac and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>etoricoxib<p>etoricoxib and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>etoricoxib and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>fenbufen and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fennel<p>naproxen and fennel both increase  anticoagulation. Use Caution/Monitor.</p></li><li>fenoprofen<p>fenoprofen and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>fenoprofen and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>feverfew<p>naproxen and feverfew both increase  anticoagulation. Use Caution/Monitor.</p></li><li>flucloxacillin<p>flucloxacillin, naproxen.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>flucloxacillin, naproxen.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>fludrocortisone<p>naproxen, fludrocortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fluoxetine<p>fluoxetine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>flurbiprofen<p>flurbiprofen and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>flurbiprofen and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fluvoxamine<p>fluvoxamine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fondaparinux<p>fondaparinux and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>formoterol<p>naproxen increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>forskolin<p>naproxen and forskolin both increase  anticoagulation. Use Caution/Monitor.</p></li><li>fosinopril<p>fosinopril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>furosemide<p>naproxen increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>garlic<p>naproxen and garlic both increase  anticoagulation. Use Caution/Monitor.</p></li><li>gemifloxacin<p>gemifloxacin, naproxen. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.</p></li><li>gentamicin<p>naproxen increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ginger<p>naproxen and ginger both increase  anticoagulation. Use Caution/Monitor.</p></li><li>ginkgo biloba<p>naproxen and ginkgo biloba both increase  anticoagulation. Use Caution/Monitor.</p></li><li>glimepiride<p>naproxen increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>glipizide<p>naproxen increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>gliquidone<p>naproxen increases effects of gliquidone by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>glyburide<p>naproxen increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>green tea<p>green tea, naproxen. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding.</p></li><li>heparin<p>heparin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>horse chestnut seed<p>naproxen and horse chestnut seed both increase  anticoagulation. Use Caution/Monitor.</p></li><li>hydralazine<p>naproxen decreases effects of hydralazine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>hydrochlorothiazide<p>naproxen increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>hydrocortisone<p>naproxen, hydrocortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>ibuprofen<p>ibuprofen and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>ibuprofen and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>imatinib<p>imatinib, naproxen.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is   coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents.</p></li><li>indapamide<p>naproxen increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>indomethacin<p>indomethacin and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>indomethacin and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>irbesartan<p>irbesartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of irbesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>irbesartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>isoproterenol<p>naproxen increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ketoprofen<p>ketoprofen and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>ketoprofen and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketorolac<p>ketorolac and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>ketorolac and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketorolac intranasal<p>ketorolac intranasal and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>ketorolac intranasal and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>labetalol<p>labetalol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>lepirudin<p>lepirudin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>levalbuterol<p>naproxen increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>levofloxacin<p>levofloxacin, naproxen. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Risk of CNS stimulation/seizure.  Mechanism: Displacement of GABA from receptors in brain.</p></li><li>levomilnacipran<p>levomilnacipran, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. SNRIs may further impair platelet activity in patients taking antiplatelet or anticoagulant drugs.</p></li><li>lisinopril<p>lisinopril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>lithium<p>naproxen increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.</p></li><li>lornoxicam<p>lornoxicam and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>lornoxicam and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>losartan<p>losartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>meclofenamate<p>meclofenamate and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>meclofenamate and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>mefenamic acid<p>mefenamic acid and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>mefenamic acid and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>melatonin<p>melatonin increases effects of naproxen by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time.</p></li><li>meloxicam<p>meloxicam and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>meloxicam and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>mesalamine<p>mesalamine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive nephrotoxicity.</p></li><li>metaproterenol<p>naproxen increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>methyclothiazide<p>naproxen increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>methylprednisolone<p>naproxen, methylprednisolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>metolazone<p>naproxen increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metoprolol<p>metoprolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of metoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>milnacipran<p>milnacipran, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mipomersen<p>mipomersen, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mistletoe<p>naproxen increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>moexipril<p>moexipril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>moxifloxacin<p>moxifloxacin, naproxen. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.</p></li><li>moxisylyte<p>naproxen decreases effects of moxisylyte by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>mycophenolate<p>naproxen will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>nabumetone<p>nabumetone and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>nabumetone and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>nadolol<p>nadolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of nadolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>nebivolol<p>nebivolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of nebivolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>nefazodone<p>nefazodone, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>nettle<p>naproxen increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>norepinephrine<p>naproxen increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>olmesartan<p>olmesartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>olmesartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ospemifene<p>naproxen, ospemifene.
Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.</p></li><li>oxaprozin<p>naproxen and oxaprozin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and oxaprozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>panax ginseng<p>naproxen and panax ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>parecoxib<p>naproxen and parecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and parecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>paroxetine<p>paroxetine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>pau d'arco<p>naproxen and pau d'arco both increase  anticoagulation. Use Caution/Monitor.</p></li><li>pegaspargase<p>pegaspargase increases effects of naproxen by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b decreases levels of naproxen by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered.</p></li><li>penbutolol<p>penbutolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of penbutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>perindopril<p>perindopril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>phenindione<p>phenindione and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>phenoxybenzamine<p>naproxen decreases effects of phenoxybenzamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>phentolamine<p>naproxen decreases effects of phentolamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>phytoestrogens<p>naproxen and phytoestrogens both increase  anticoagulation. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of pindolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>pirbuterol<p>naproxen increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>piroxicam<p>naproxen and piroxicam both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and piroxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>pivmecillinam<p>pivmecillinam, naproxen.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>pivmecillinam, naproxen.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>potassium acid phosphate<p>naproxen and potassium acid phosphate both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium chloride<p>naproxen and potassium chloride both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium citrate<p>naproxen and potassium citrate both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>pralatrexate<p>naproxen increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.</p></li><li>prazosin<p>naproxen decreases effects of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>prednisolone<p>naproxen, prednisolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>prednisone<p>naproxen, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>probenecid<p>naproxen will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>propranolol<p>propranolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of propranolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>protamine<p>protamine and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>quinapril<p>quinapril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ramipril<p>ramipril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>reishi<p>naproxen and reishi both increase  anticoagulation. Use Caution/Monitor.</p></li><li>reteplase<p>naproxen and reteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.</p></li><li>rivastigmine<p>rivastigmine increases toxicity of naproxen by pharmacodynamic synergism. Use Caution/Monitor. Monitor patients for symptoms of active or occult gastrointestinal bleeding.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sacubitril/valsartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.<span><br><br></span>naproxen decreases effects of sacubitril/valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.</p></li><li>salicylates (non-asa)<p>naproxen and salicylates (non-asa) both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and salicylates (non-asa) both increase  serum potassium. Use Caution/Monitor.</p></li><li>salmeterol<p>naproxen increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>salsalate<p>naproxen and salsalate both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and salsalate both increase  serum potassium. Use Caution/Monitor.</p></li><li>saw palmetto<p>saw palmetto increases toxicity of naproxen by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding.</p></li><li>sertraline<p>sertraline, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>siberian ginseng<p>naproxen and siberian ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>silodosin<p>naproxen decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>sodium picosulfate/magnesium oxide/anhydrous citric acid<p>naproxen, sodium picosulfate/magnesium oxide/anhydrous citric acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May be associated with fluid and electrolyte imbalances.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>naproxen, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>naproxen, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sotalol<p>sotalol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>spironolactone<p>spironolactone and naproxen both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>succinylcholine<p>naproxen and succinylcholine both increase  serum potassium. Use Caution/Monitor.</p></li><li>sulfasalazine<p>naproxen and sulfasalazine both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and sulfasalazine both increase  serum potassium. Use Caution/Monitor.</p></li><li>sulindac<p>naproxen and sulindac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and sulindac both increase  serum potassium. Use Caution/Monitor.</p></li><li>telmisartan<p>telmisartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of telmisartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>telmisartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>temocillin<p>temocillin, naproxen.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>temocillin, naproxen.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>tenecteplase<p>naproxen and tenecteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.</p></li><li>tenofovir df<p>tenofovir df, naproxen.
Either increases levels of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of  tenofovir DF with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.</p></li><li>terazosin<p>naproxen decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>terbutaline<p>naproxen increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ticarcillin<p>ticarcillin, naproxen.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>ticarcillin, naproxen.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>timolol<p>timolol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>tinzaparin<p>tinzaparin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>tobramycin inhaled<p>tobramycin inhaled and naproxen both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity</p></li><li>tolazamide<p>naproxen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolbutamide<p>naproxen increases effects of tolbutamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolfenamic acid<p>naproxen and tolfenamic acid both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and tolfenamic acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolmetin<p>naproxen and tolmetin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>naproxen and tolmetin both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolvaptan<p>naproxen and tolvaptan both increase  serum potassium. Use Caution/Monitor.</p></li><li>torsemide<p>naproxen increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>trandolapril<p>trandolapril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>trazodone<p>trazodone, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>triamcinolone<p>naproxen, triamcinolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>triamterene<p>triamterene and naproxen both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>valsartan<p>valsartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>venlafaxine<p>venlafaxine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>vitamin k1 (phytonadione)<p>naproxen increases and vitamin k1 (phytonadione) decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>vorapaxar<p>naproxen, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur.</p></li><li>vortioxetine<p>naproxen, vortioxetine.
Either increases effects of the other by anticoagulation. Use Caution/Monitor.</p></li><li>warfarin<p>warfarin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>zotepine<p>naproxen decreases effects of zotepine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li>